BioVaxys Technology Corp.

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

BioVaxys Announces Positive Preliminary Results from PESCO Study Evaluating MVP-S Combination Therapy in Recurrent Epithelial Ovarian Cancer

BioVaxys Reports Positive Clinical Study Results from Phase 1b/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda(TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

BioVaxys Technology Corp. Announces Highly Promising Results from Phase 1 Clinical Study of MVP-S and DPX-SurMAGE Cancer Vaccines in Patients with Non-Muscle Invasive Bladder Cancer

BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

BioVaxys Provides 2025 Corporate Review

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Interim MD&A - English.pdf

Interim financial statements/report – English.pdf

Interim MD&A - English.pdf

Interim financial statements/report – English.pdf